Medical hexing: By direct-to-consumer advertising Merck killed 60,000 people
By Dr. Mercola
May 14, 2012 [
articles.mercola.com]
What would you say if you knew someone had killed 60,000 people? Would you call it a felony of the worst kind, times 60,000? If you totaled up the value of all those lives in criminal court, what would you say they're worth?
Billions? Trillions?
Or—how about a measly $321 million in exchange for a guilty plea to a misdemeanor? When you consider that this involves the second-largest drug maker in the U.S.—Merck—and its deadly drug Vioxx, then you'll probably agree that a misdemeanor and a $321 million fine amounts to nothing more than a slap on the wrist.
Business analysts were estimating a $25 billion judgment when the drug was taken off the market, but even when combined with the $4.85 billion in payouts to patients who suffered heart attacks and strokesi, the final bill is nowhere close to original estimates of the damage.
Yet that's the plea agreement Merck recently made with a federal court in Boston on April 19th, after being charged with
illegal promotion of Vioxx for treatment of rheumatoid arthritis, before it was approved for that use.
The sad tale brings up memories of what I tried to warn readers about in 1999, when I showed that people taking this drug were at a massively increased risk of dying from heart disease and stroke. It's tragic that Vioxx was removed only AFTER 60,000 people died.
It's even more tragic that a court would consider Merck's illegal promotion of the drug a misdemeanor rather than a felony, since this tactic clearly exposed far more people to the dangerous drug than it would have otherwise. And, adding insult to injury, instead of the billions that Merck anticipated paying out, it got away with such a paltry sum.
Hired Writers Responsible for Some of Merck's Vioxx Studies?
Particularly galling is the fact that these deaths could have been so easily avoided, were it not for the deceptive maneuvering of parties who stood to profit handsomely from the success of the drug.
Ghostwriting has become an increasingly troublesome problem in the medical science community, and the Vioxx debacle is a perfect example of why ghostwriting medical research is a devious practice that needs to be rooted out.
Merck has previously acknowledged that it has been known to hire professional writers to develop research-related documents that eventually get published under the name of reputable leaders in the medical community. Critics rightfully doubt the validity of such research, and question the actual involvement of the scientists listed as authors of these ghostwritten papers.
Back in 2008, Dr. Joseph S. Ross of New York's Mount Sinai School of Medicine came across ghostwritten research studies for Vioxx while reviewing documents related to lawsuits filed against Merck.
According to an April 16, 2008 article on MedHeadlines:
"In about 96 journal publications, Ross and his colleagues discovered internal Merck documents and e-mail messages pertaining to clinical study reports and review articles, some of which were developed by the company's marketing department, not its scientific department. In others, there is little evidence that the authors recruited for the report made substantial contribution to the research itself. ... Some of the authors listed in the Merck study reports of concern... question the true nature of ghostwriting. One neurologist originally listed as "External author?" and then listed as Dr. Leon J. Thal, of the University of California, San Diego in the final draft, died a year ago in an airplane crash."
An editorial published in the Journal of the American Medical Association (JAMA) that year by Drs. Psaty and Kronmal also questioned whether Merck might have deliberately manipulated dozens of academic documents published in the medical literature, in order to promote Vioxx under false pretenses.
Blockbuster Drugs Tend to Be More Unnecessary than Others
Vioxx was a so-called blockbuster drug—a designation given to extremely popular drugs that generate a minimum of $1 billion in annual sales. Vioxx was marketed in more than 80 countries, and pulled in $2.5 billion in worldwide sales in 2003 alone (the year before it was pulled from the market due to its heart risks). So despite paying out fines in various lawsuits over the drug, Merck certainly made enough from it to cover all such expenses and still make obscene profits while patients were dying in droves.
An important strategy for creating a true blockbuster drug—at least in the United States—is the use of direct to consumer advertising.
A little over 20 years ago direct-to-consumer advertising for drugs was not allowed in the US. Drug advertising is still illegal in most countries around the world, except for the US. If Big Pharma wanted to sell a product, they had to do it through the person prescribing it—your doctor. If a physician didn't have time to listen to sales reps or attend conferences where new drugs were pushed, well then, sometimes they just didn't get pushed on you.
But ever since drug advertising became legal in the U.S., Big Pharma has been making big bucks selling you pills that not only are expensive, but intended to keep you hooked on them for life. As with most advertised consumer products, drugs with blockbuster potential are not necessarily important life-saving drugs. No, rather than curing actual disease, these drugs tend to be focused on the treatment of symptoms—symptoms that many people tend to experience and which may or may not be caused by a particular disease...
Oftentimes, symptom complexes will be given official-sounding designations, to make it appear more like an actual disease. Either way, since these types of drugs cannot cure anything, they must be taken indefinitely—until you die or cannot afford them anymore. According to Melody Petersen, author of Our Daily Meds:
"Most blockbusters are pills for conditions such as anxiety, high cholesterol or constipation that must be taken daily, often for months or years. They are designed for rich Americans who can afford to buy them."
[continue [
articles.mercola.com]
Edited 1 time(s). Last edit at 05/01/2016 02:58PM by Moerk.